Zheng Li
Advertisement
Articles by Zheng Li
21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial
ByGabriel N. Hortobagyi, MD, FACP,Daniil Stroyakovskiy,Denise A. Yardley, MD,Chiun-Sheng Huang,Peter A. Fasching,John Crown,Aditya Bardia, MD, MPH, FASCO,Stephen Chia,Seock-Ah Im,Miguel Martin, MD, PhD,Sherene Loi, MD, PhD,Binghe Xu,Sara A. Hurvitz, MD,Carlos Barrios,Michael Untch, MD, PhD,Rebecca Moroose,Frances Visco,Federico Parnizari,Farhat Ghaznawi,Zheng Li,Sorcha Waters,Arunava Chakravartty,Dennis J. Slamon, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
2
FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC
3
How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?
4
EMD Associated With Poorer Outcomes in Previously Treated R/R Multiple Myeloma
5
